Hosted on MSN1mon
GSK gets expanded EU approval for Jemperli in endometrial cancer
GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...
Hosted on MSN1mon
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 32.8%. VYGR’s earnings beat ...
pharmaphorum1y
Jemperli cleared for frontline use in endometrial cancer
GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...
pharmaphorum1mon
GSK claims a first with Jemperli in endometrial cancer
GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...